---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006039"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:27:52.713897+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arbutus Q3 net loss $19.7M; imdusiran/AB-101 data upcoming; cash into Q4 2026

## Summary
- Net loss $19.7M ($0.10 per share) vs $20.1M prior year; revenue fell to $1.3M from $4.7M on lower license and royalty income.
- Cash and investments $130.8M; 2024 cash burn expected $63M-$67M; runway into Q4 2026.
- Imdusiran HBsAg loss data from IM-PROVE I/II to be presented at AASLD Nov 2024; additional follow-up and nivolumab cohort data.
- AB-101 oral PD-L1 inhibitor advanced to Part 3 in cHBV patients; preliminary data expected H1 2025.
- LNP litigation vs Moderna trial set Sept 2025; Pfizer claim construction Dec 18, 2024; restructuring charge $3.6M.

## SEC filing metadata
- accession: 0001171843-24-006039
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324006039/0001171843-24-006039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324006039/f8k_110624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006039
- JSON: https://secwatch.observer/filing/0001171843-24-006039.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.